Coherus Oncology (CHRS) EBIT Growth (1y) (2014 - 2026)

Coherus Oncology (CHRS) EBIT Growth (1y) (2014 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Growth (1y) (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -24.89%
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 2,150.96%
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 80.62%
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 8.65%
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 145.20%
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Coherus Oncology 195.05 Mn 28.00 Mn 8.50 Mn 20.43%

Historic Data

Download Data
DateValue
Mar 31, 2026 20.43%
Dec 31, 2025 -1.09%
Sep 30, 2025 5.38%
Jun 30, 2025 -14.79%
Mar 31, 2025 32.97%
Dec 31, 2024 34.14%
Sep 30, 2024 -46.40%
Jun 30, 2024 -14.71%
Mar 31, 2024 -0.06%
Dec 31, 2023 -33.81%
Sep 30, 2023 60.22%
Jun 30, 2023 21.52%
Mar 31, 2023 16.29%
Dec 31, 2022 -30.21%
Sep 30, 2022 -145.37%
Jun 30, 2022 -82.14%
Mar 31, 2022 51.65%
Dec 31, 2021 -340.77%
Sep 30, 2021 -197.24%
Jun 30, 2021 -137.00%